EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unleashing the anti-tumor angiogenic potential of nano-formulated orientin: In Silico, In Vitro, and In Ovo studies

Yashwanth Elumalai iD, Kathiresan Nachammai, Kirubhanand Chandrasekaran, Langeswaran Kulanthaivel, Sharon Benita Stephen, Kanu Shil, Ram Kumar Anandan, Abdulhadi Ibrahim Bima, Zeenath Khan, Abdulhadi S Burzangi, Noor A Shaik, Nuha Al-Rayes und 1 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0322564 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Yashwanth Elumalai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Allied Health Science, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamil Nadu, In…. Hauptthemen laut MEDLINE: Flavonoids, Angiogenesis Inhibitors, Glucosides, Neovascularization, Pathologic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Abdulaziz University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The study investigated the potential of nano-formulated orientin (NF-O) in the anti-angiogenic cancer therapy. Orientin is a flavonoid that has a promising effect against anti-inflammatory, anti-oxidant, and anti-arrhythmia properties. Nano-formulation aimed to overcome this limitation and also served to enhance its therapeutic efficacy. In silico docking studies, the favorable binding of orientin was identified with the key oncogenic targets (EGFR, ALK, KRAS, NTRK). After nano-formulation, UV spectroscopy confirmed the integrity of orientin with no shift in the λmax (347 nm). Dynamic light scattering showed a significant reduction in the improved particle size (PDI decreased from 0.863 to 0.173) by nano-formulation from 559 nm to 220 nm. Fourier Transform infrared spectroscopy analysis confirmed that the nano-formulation process did not alter the chemical structure of orientin. In-vitro studies using MCF-7 breast cancer cells showed that NF-O inhibited cell growth and reduced viability in a dose-dependent manner. At 10 µM, NF-O significantly inhibited the cell growth and migration compared to the control and native orientin in wound healing assays (p < 0.01). In ova, using the chick chorioallantoic membrane (CAM) assay, NF-O (10 µg/ml) significantly inhibited angiogenesis by reducing blood vessel density, branching, length, and network formation compared to controls and native orientin. These findings suggest that NF-O holds significant promise as a novel anti-angiogenic agent for the cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlavonoidsAngiogenesis InhibitorsGlucosidesNeovascularization, PathologicNanoparticlesHumansAnimalsChick EmbryoMCF-7 CellsCell MovementCell ProliferationMolecular Docking SimulationCell SurvivalChorioallantoic MembraneSpectroscopy, Fourier Transform InfraredComputer SimulationFemaleParticle Size

Substanzen

FlavonoidsAngiogenesis InhibitorsorientinGlucosides

Autor:innen und Institutionen

  • Faculty of Allied Health Science, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamil Nadu, India.
  • Department of Biotechnology, Alagappa University, Karaikudi, Tamil Nadu, India.
  • Department of Anatomy, AIIMS, Nagpur, India.
  • Faculty of Paramedical Sciences, Assam Down town University, Guwahati, Assam, India.
  • Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India.
  • Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

ORCID-Profile: Yashwanth Elumalai, Gowtham Kumar Subbaraj

Förderung

  • King Abdulaziz University

Zitieren

APA

Elumalai, Y., Nachammai, K., Chandrasekaran, K., Kulanthaivel, L., Stephen, S. B., Shil, K., Anandan, R. K., Bima, A. I., Khan, Z., Burzangi, A. S., Shaik, N. A., Al-Rayes, N., & Subbaraj, G. K. (2025). Unleashing the anti-tumor angiogenic potential of nano-formulated orientin: In Silico, In Vitro, and In Ovo studies. PLOS One. https://doi.org/10.1371/journal.pone.0322564

Vancouver

Elumalai Y, Nachammai K, Chandrasekaran K, Kulanthaivel L, Stephen SB, Shil K, et al. Unleashing the anti-tumor angiogenic potential of nano-formulated orientin: In Silico, In Vitro, and In Ovo studies. PLOS One. 2025. doi:10.1371/journal.pone.0322564

BibTeX
@article{Elumalai2025,
  author = {Elumalai, Yashwanth and Nachammai, Kathiresan and Chandrasekaran, Kirubhanand and Kulanthaivel, Langeswaran and Stephen, Sharon Benita and Shil, Kanu and Anandan, Ram Kumar and Bima, Abdulhadi Ibrahim and Khan, Zeenath and Burzangi, Abdulhadi S and Shaik, Noor A and Al-Rayes, Nuha and Subbaraj, Gowtham Kumar},
  title = {Unleashing the anti-tumor angiogenic potential of nano-formulated orientin: In Silico, In Vitro, and In Ovo studies},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0322564}
}
Kostenlos starten →